ACT Treats Fourth Patient With Higher Cell Therapy Dosage
Advanced Cell Technology of Marlborough has treated its fourth patient in its U.S. clinical trial for Stargardt's mascular dystrophy (SMD), this time using a higher dosage of retinal pigment epithelial (RPE) cells, which are derived from human embryonic stem cells.
The patient was the first to be treated in a second cohort of trials. The first cohort was completed in February.
The surgery was performed July 11 at the Wills Eye Institute in Philadelphia, according to a statement by ACT. The patient, who was injected with 100,000 RPE cells—double the amount patients in the first cohort received—is recovering uneventfully, according to ACT.
"Doubling the cell dosage marks an important milestone in our clinical programs," said Robert Lanza, ACT's chief scientific officer. "We look forward to continued progress and safety findings in the coming months, in both our U.S. and European trials."
The Phase I/II trial was initiated in July 2011, and is designed to determine the safety of treatment with RPE cells in SMD patients who have undergone sub-retinal transplantation. The trial will involve a total of 12 patients.
Read more
Marlborough Firm ACT Hails Stem Cell Ruling
ACT Secures $35M In Stock Deal
WBJ Web Partners
Most Recent
Most Recent
0 Comments